Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE (0.04%), DAX +0.66%, CAC40 +0.09%

Oct 16 ,2026

  • Synopsis

    • European indicies are set to open mixed with Asian equities strengthening Friday. Semis/memory rebounding, driving outperformance of Japan, South Korea and Taiwan benchmarks.

    • US equities closed higher in Thursday trading, ending near best levels. Equal-weight S&P 500 (RSP) outperformed cap-weighted index by ~100 bp.

    • Thursday continuing to see weakness across the AI trade and continuation of Wednesday's defensive rotations.

    • Friday sees, in central banks, BOE's Bailey in conversation at 3:00BST at event hosted by IIF and Bundesbank's Nagel and minister of finance Klingbeil press conf. at 4:30CET at IMF annual meeting. Spain's minister of economy, trade, and business Cuerpo in conversation at Atlantic Council at IMF on growth, trade, and Europe's economic path.

    • Earnings reported early today: (CMCOM.NA) CM.com reports Q3 net income €1M vs year-ago (€2.4M); 2026 outlook raised. (SU.FP) Schneider Electric reports Q3 revenue €11.46B vs consensus €11.13B; upgrades its FY26 financial target. (AZA.SS) Avanza Bank Holding reports Q3 EPS SEK4.90 vs FactSet SEK5.05.

    • Economic data due today: Italy Sep final CPI, Aug trade balance, Eurozone Sep final CPI, Aug trade balance, Sweden Sep unemployment rate, Austria Sep final CPI

    • Other news include: (DLG.IM) De'Longhi increases its stake to 88% in professional division; pays total cash consideration of approximately €662.5M. (PPGN.SW) Samsung Peptide announces definitive interim result of its public tender offer for PolyPeptide Group; transaction is currently expected to be completed towards the end of 2026 or in Q1 2027

  • Politics/Macro/World News

    • Europe Reckons With a World Where Trump Is Now Helping Putin (Bloomberg )

    • France and Germany agree to ease EU car emissions rules in new deal (France24 )

    • BOE's Bailey Sees Little Evidence of Second-Round Inflation (BBG )

    • Banks say Healey is planning Budget tax raid on their profits (BBC )

  • Top company news

    • Earnings/updates

      • AIXA.GR (Aixtron) -- announces Q3 2026 order intake and operating profitability significantly exceed market expectations

      • BC.IM (Brunello Cucinelli) -- reports Q3 revenue €374.2M vs StreetAccount €371.1M; revises 2026 outlook further upwards

      • NDX1.GR (Nordex) -- reports preliminary Q3 EBITDA ~€278M vs FactSet €230.6M [5 est, €219-247M]

      • ADP.FP (Aeroport de Paris) -- reports Total Paris Aeroport Septermber traffic 9.08M (1.6%) y/y; revises 2026 traffic outlook lower

      • MMB.FP (Lagardere) -- reports preliminary Q3 revenue €2.63B vs year-ago €2.55B

      • ALHG.FP (Louis Hachette Group SA) -- reports Q3 revenue €2.68B vs FactSet €2.66B

      • THEP.FP (Thermador Groupe) -- reports Q3 revenue €129.0M vs FactSet €130.0M [1 est]

      • ALCPB.FP (Capital B) -- reports H1 net income (€69.5M) including BTC impairment charge

      • 0IFR.LN (ChronoScale Holdings Corp.) -- reports Q1 EPS (cont ops) ($0.18) vs year-ago ($0.08)

    • M&A

      • CBK.GR (Commerzbank) -- UniCredit receives ECB approval to acquire control of Commerzbank

      • PPGN.SW (PolyPeptide Group) -- Samsung Peptide announces definitive interim result of its public tender offer for PolyPeptide Group; transaction is currently expected to be completed towards the end of 2026 or in Q1 2027

      • CWY.AU (Cleanaway Waste Management) -- responds to ASX price query; not aware of any information that could explain recent trading

    • Healthcare

      • SAN.FP (Sanofi) -- and pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Dupixent Across Four Indications in Dermatology and Respiratory Care

      • ROP.SW (Roche Holding) -- FDA approves Genentech's Enspryng, a first-in-Class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

      • NYXH.BB (Nyxoah) -- provides full 12-Month data from the ACCCESS U.S. pivotal study in complete concentric collapse patients presented at ISSS 2026

      • AVCT.LN (Avacta Group) -- Transcript Intelligence: Avacta Group Investor Meeting

    • Other

      • ASML.NA (ASML Holding) -- Street Takeaways - ASML Holding Q3 Earnings

      • ML.FP (Cie Generale des Etablissements Michelin SA) -- Michelin publishes global tire market data for September

      • ALO.FP (Alstom) -- signs 15-year services contract extension worth ~£800M from Greater Anglia in the United Kingdom

      • FER.SM (Ferrovial) -- selected to deliver Georgia's I-285 East Express Lanes

      • EU Commission anticipated to give fast-track antitrust approval to satellite company being formed by Leonardo, Airbus, and Thales, known as Project Bremo - Bloomberg

      • Vodacom issues update on acquisition of a controlling interest in Safaricom PLC

  • Key rating changes

    • Upgrades

      • Peel Hunt re-initiates CMCX.LN; transfers IGG.LN, PLUS.LN

      • BYIT.LN (Bytes Technology Group) to neutral from underperform at BNP Paribas Exane

    • Downgrades

      • SIE.GR (Siemens AG) -- to hold from buy at Jefferies, we're told

      • LLOY.LN (Lloyds Banking Group) to sector perform from outperform at RBC Capital Markets

    • Initiations

      • AJB.LN (AJ Bell) -- hold at Peel Hunt

      • EN.FP (Bouygues) -- buy at UBS

  • Data

    • Nikkei +1.86% to 65621.54

    • Hang Seng +1.01% to 24306.87

    • Shanghai Composite +0.39% to 3722.08

    • S&P futures +12.0 vs prior close of 7791.0

    • €-$ +0.0004 or +0.04% to 1.1226

    • $-¥ (0.10) or (0.06%) to 157.89

    • €-¥ (0.04) or (0.02%) to 177.25

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.